Cybin Inc. Common Stock — Rendiconto Finanziario Trimestrale (NASDAQ:HELP)

Financials

Market Capitalization 118.81 M
Employee 50
Founded 2019
CEO N/A
Website www.helus.com
Headquarter Ontario, Canada
FIGI BBG00MFNRRT4
Industry Technology

118.81 M Capitalizzazione di mercato

Cybin Inc

Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines. The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010. As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development. In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025.